A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
Sponsored by Novo Nordisk A/S
About this study
The purpose of this study is to find out if zenagamtide is safe and effective for treating participants who have excess body weight compared to treatment with semaglutide.
Where this study is enrolling (3)
- I'm interested
The Endocrine Center
Houston, Texas
- I'm interested
Olympus Clinical Research
Sugar Land, Texas
- I'm interested
Houston Research Institute
Houston, Texas
Who can participate
Inclusion criteria
- ✓Male or female (sex at birth).
- ✓Age 18 years or above at the time of signing the informed consent.
Exclusion criteria
- ✕Glycated haemoglobin (HbA1c) ≥ 6.5% (48 millimoles per mole \[mmol/mol\]) as measured by the central laboratory at screening.
- ✕History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records.
- ✕Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues within 1 year before screening.
Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.